88P - Color Doppler parameters: a non invasive prognostic marker in carcinoma breast in both naive and neoadjuvant chemotherapy patients.

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Breast Cancer, Early Stage
Staging procedures (clinical staging)
Presenter H B Govardhan
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors H.B. Govardhan1, S. Pradhan2, R. Jain3, K. Ibrahim A1, P. Sridhar1
  • 1Radiation Oncology, Kidwai Memorial Institute of Oncology, 560029 - Bangalore/IN
  • 2Radiation Medicine And Radiotherapy, Institute of Medical Sciences, Banaras Hindu University,IMS-BHU, 221001 - Varanasi/IN
  • 3Radiation Oncology, Pt.J.N.M.Medical College Raipur, Raipur - Raipur/IN



To investigate the role of color Doppler parameters in carcinoma breast as non invasive prognostic marker.


A total of 92 patients o carcinoma of breast who are all candidate for surgery were underwent color Doppler study, RI (resistivity index), PI(pulsatality Index) and Vmax were documented. All these Doppler parameters were graded as per standard guideline(grade1-4). These color dopplers grading were correlated with histopathological findings like tumor size, lymph node, histopathological grade. On follow up data, the color Doppler grades were also compared and correlated with overall survival and disease free survival at 5 years. Appropriate statistics were used or analysis.


Out of 92 patients all patients were able to correlate the Doppler parameters (PI, RI, VMax) with histopathological parameters(size, Lymph node and grade). Out o 92 patients 30 patients were received neoadjuvant chemotherapy. For all patients, the results were already presented elsewhere, now we are concentrating on patients with NACT. For follow up data only 56 patients were available to calculate overall survival and DFS. PI were correlated with tumor size, lymph node number, grade were- 0.675 (p  0.05): 0.518(p 


Color Doppler can be one of the prognostic factor in carcinoma breast in both naive and patients undergoing neoadjuvant chemotherapy. Due to its non invasiveness, and its predictiveness it is very important tool in patients undergoing or neoadjuvant chemotherapy.

Clinical trial indentification


Legal entity responsible for the study





All authors have declared no conflicts of interest.